Tags

Type your tag names separated by a space and hit enter

Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions.
Gynecol Oncol. 2015 Jan; 136(1):3-7.GO

Abstract

Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancers as well as a 9-12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome.

Authors+Show Affiliations

H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA. Electronic address: Johnathan.lancaster@moffitt.org.Permanente Medical Group San Francisco, CA, USA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.The University of Texas Southwestern Medical Center, Dallas, TX, USA.No affiliation info available

Pub Type(s)

Journal Article
Practice Guideline

Language

eng

PubMed ID

25238946

Citation

Lancaster, Johnathan M., et al. "Society of Gynecologic Oncology Statement On Risk Assessment for Inherited Gynecologic Cancer Predispositions." Gynecologic Oncology, vol. 136, no. 1, 2015, pp. 3-7.
Lancaster JM, Powell CB, Chen LM, et al. Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2015;136(1):3-7.
Lancaster, J. M., Powell, C. B., Chen, L. M., & Richardson, D. L. (2015). Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. Gynecologic Oncology, 136(1), 3-7. https://doi.org/10.1016/j.ygyno.2014.09.009
Lancaster JM, et al. Society of Gynecologic Oncology Statement On Risk Assessment for Inherited Gynecologic Cancer Predispositions. Gynecol Oncol. 2015;136(1):3-7. PubMed PMID: 25238946.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Society of Gynecologic Oncology statement on risk assessment for inherited gynecologic cancer predispositions. AU - Lancaster,Johnathan M, AU - Powell,C Bethan, AU - Chen,Lee-May, AU - Richardson,Debra L, AU - ,, Y1 - 2014/09/17/ PY - 2014/04/29/received PY - 2014/09/03/revised PY - 2014/09/09/accepted PY - 2014/9/21/entrez PY - 2014/9/23/pubmed PY - 2015/3/3/medline KW - BRCA1 KW - BRCA2 KW - Cowden syndrome KW - Genetic testing KW - Hereditary cancer KW - Lynch syndrome SP - 3 EP - 7 JF - Gynecologic oncology JO - Gynecol Oncol VL - 136 IS - 1 N2 - Women with germline mutations in the cancer susceptibility genes, BRCA1 or BRCA2, associated with Hereditary Breast & Ovarian Cancer syndrome, have up to an 85% lifetime risk of breast cancer and up to a 46% lifetime risk of ovarian, tubal, and peritoneal cancers. Similarly, women with mutations in the DNA mismatch repair genes, MLH1, MSH2, MSH6, or PMS2, associated with the Lynch/Hereditary Non-Polyposis Colorectal Cancer (HNPCC) syndrome, have up to a 40-60% lifetime risk of both endometrial and colorectal cancers as well as a 9-12% lifetime risk of ovarian cancer. Mutations in other genes including TP53, PTEN, and STK11 are responsible for hereditary syndromes associated with gynecologic, breast, and other cancers. Evaluation of the likelihood of a patient having one of these gynecologic cancer predisposition syndromes enables physicians to provide individualized assessments of cancer risk, as well as the opportunity to provide tailored screening and prevention strategies such as surveillance, chemoprevention, and prophylactic surgery that may reduce the morbidity and mortality associated with these syndromes. Evaluation for the presence of a hereditary cancer syndrome is a process that includes assessment of clinical and tumor characteristics, education and counseling conducted by a provider with expertise in cancer genetics, and may include genetic testing after appropriate consent is obtained. This commentary provides guidance on identification of patients who may benefit from assessment for the presence of a hereditary breast and/or gynecologic cancer syndrome. SN - 1095-6859 UR - https://www.unboundmedicine.com/medline/citation/25238946/Society_of_Gynecologic_Oncology_statement_on_risk_assessment_for_inherited_gynecologic_cancer_predispositions_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0090-8258(14)01312-2 DB - PRIME DP - Unbound Medicine ER -